Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors

被引：0
|
作者：
Chenard-Poirier, Maxime
Almhanna, Khaldoun
Lim, Darren Wan-Teck
El-Khoueiry, Anthony B.
Samol, Jens
Ryoo, Baek-Yeol
Hong, Jung Yong
Meng, Robin
Abbadessa, Giovanni
Masciari, Serena
Kefsi, Asma
Zhang, Yiding
Guillemin-Paveau, Helene
Pasquier, Benoit
Lepine, Lucie
Dumbrava, Ecaterina Elena
机构：
[1] CHU Quebec Univ Laval, Quebec City, PQ, Canada
[2] Brown Univ, Lifespan Canc Inst, Warren Alpert Med Sch, Providence, RI USA
[3] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[4] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Tan Tock Seng Hosp, Singapore, Singapore
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Lee Kong Chian NTU, Singapore, Singapore
[8] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[10] Sanofi, Cambridge, MA USA
[11] Sanofi, Vitry Sur Seine, France
[12] Sanofi, Chilly Mazarin, France
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2579
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
    Muhammad Wasif Saif
    Carlos R. Becerra
    Marwan G. Fakih
    Weijing Sun
    Lazar Popovic
    Smitha Krishnamurthi
    Thomas J. George
    Michelle A. Rudek
    Dale R. Shepard
    Jiri Skopek
    Vladimir Sramek
    Bojan Zaric
    Ikuo Yamamiya
    Karim A. Benhadji
    Kensuke Hamada
    Yaohua He
    Lee Rosen
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 485 - 497
  • [22] A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Mingxiang Liao
    Krzysztof G. Jeziorski
    Monika Tomaszewska-Kiecana
    István Láng
    Marek Jasiówka
    Viera Skarbová
    Piotr Centkowski
    Rodryg Ramlau
    Maria Górnaś
    John Lee
    Sarah Edwards
    Jenn Habeck
    Eileen Nash
    Nikolay Grechko
    Jim J. Xiao
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 887 - 897
  • [23] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Asahina, Hajime
    Tamura, Yosuke
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Seki, Yoshitaka
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Yamada, Yasuhide
    Coates, Andrew
    Chiu, Yi-Lin
    Li, Xiaohui
    Pradhan, Rajendra
    Ansell, Peter J.
    McKeegan, Evelyn M.
    McKee, Mark D.
    Carlson, Dawn M.
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1477 - 1486
  • [24] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Hajime Asahina
    Yosuke Tamura
    Hiroshi Nokihara
    Noboru Yamamoto
    Yoshitaka Seki
    Takashi Shibata
    Yasushi Goto
    Maki Tanioka
    Yasuhide Yamada
    Andrew Coates
    Yi-Lin Chiu
    Xiaohui Li
    Rajendra Pradhan
    Peter J. Ansell
    Evelyn M. McKeegan
    Mark D. McKee
    Dawn M. Carlson
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1477 - 1486
  • [25] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [26] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
    Dasari, Arvind
    Kauh, John S.
    Tucci, Christopher
    Nanda, Shivani
    Kania, Marek K.
    Carlisle, Jennifer W.
    Paulson, Andrew Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Slingerland, Marije
    Hess, Dagmar
    Clive, Sally
    Sharma, Sunil
    Sandstrom, Per
    Loman, Niklas
    Porro, Maria G.
    Mu, Song
    Waldron, Edward
    Valera, Sue-zette
    Gelderblom, Hans
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1089 - 1098
  • [28] An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment
    Kelly, Kevin R.
    Gabrail, Nashat Y.
    Edenfield, William J.
    Lockhart, A. Craig
    Olszanski, Anthony J.
    Reddy, Guru
    BLOOD, 2015, 126 (23)
  • [29] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sunil Sharma
    Petronella O. Witteveen
    Martijn P. Lolkema
    Dagmar Hess
    Hans Gelderblom
    Syed A. Hussain
    Maria G. Porro
    Edward Waldron
    Sue-zette Valera
    Song Mu
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 87 - 95
  • [30] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sharma, Sunil
    Witteveen, Petronella O.
    Lolkema, Martijn P.
    Hess, Dagmar
    Gelderblom, Hans
    Hussain, Syed A.
    Porro, Maria G.
    Waldron, Edward
    Valera, Sue-zette
    Mu, Song
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 87 - 95
12345